Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNZ-2591 in Pediatric Phelan-McDermid Syndrome
NCT07281079Phase 3Recruiting
- Sponsor
- Neuren Pharmaceuticals Limited
- Start
- Nov 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 2
01
Overview
A Phase 3 trial of NNZ-2591 in Phelan-McDermid syndrome (PMS), sponsored by Neuren Pharmaceuticals Limited. Started Nov 2025; status: recruiting.
02
Drugs
NNZ-2591
03
Conditions
Phelan-McDermid syndrome (PMS)
Beyond the preview
Go deeper on NCT07281079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281079.